Abstract
The authors used l-selectin to stratify the PML risk of individual MS patients undergoing natalizumab treatment. Absence of l-selectin on CD4+ T cells was sensitive (0% false-negatives) and specific (<3% of potential false-positives) in predicting individual PML risk. Biyearly checks of l-selectin levels may help in reducing the rate of natalizumab-related PML. ![Graphic][1] See p. 865; Editorial, p. 858 The authors assessed immunocompetence in 24 patients after alemtuzumab by measuring antibody responses to 3 vaccines: diphtheria, tetanus and poliomyelitis; Haemophilus influenzae type b and meningococcal group C conjugate; and pneumococcal polysaccharide. Patients with … [1]: /embed/inline-graphic-1.gif
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call